Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1819-1826

  Zhang, Sheng ^a   Feng, Xiang Ling ^b   Shi, Lei ^a   Gong, Chao Jian ^a   He, Zhi Jing ^a   Wu, Han Jiang ^a   Ling, Tian You ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

Biomarker; CpG island; DNA methylation; Microarray; Tongue squamous cell carcinoma

Indexed keywords

ARTICLE; BCL2L14 GENE; CDCP1 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIRAS3 GENE; DNA METHYLATION; FBLN1 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN TISSUE; ITIH5 GENE; METHYLATED DNA IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; RUNX3 GENE; TONGUE CARCINOMA; UPREGULATION;

ANTIGENS, CD; BCL-X PROTEIN; CALCIUM-BINDING PROTEINS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASM PROTEINS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RHO GTP-BINDING PROTEINS; RNA, MESSENGER; TONGUE NEOPLASMS; UP-REGULATION;

EID: 84876233480     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2309     Document Type: Article

References (51)

1. Markopoulos AK: Current aspects on oral squamous cell carcinoma. Open Dent J 6: 126-130, 2012.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Choi S and Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 87: 14-32, 2008.
4. Demokan S and Dalay N: Role of DNA methylation in head and neck cancer. Clin Epigenetics 2: 123-150, 2011.
5. González-Ramírez I, García-Cuellar C, Sánchez-Pérez Y and Granados-García M: DNA methylation in oral squamous cell carcinoma: molecular mechanisms and clinical implications. Oral Dis 17: 771-778, 2011.
6. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B and Ecker JR: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462: 315-322, 2009.
7. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL and Schubeler D: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37: 853-862, 2005. (Pubitemid 41077111)
8. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21, 2002.
9. Carvalho RH, Haberle V, Hou J, van Gent T, Thongjuea S, van Ijcken W, Kockx C, Brouwer R, Rijkers E, Sieuwerts A, Foekens J, van Vroonhoven M, Aerts J, Grosveld F, Lenhard B and Philipsen S: Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin 5: 9, 2012.
10. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J and Sidransky D: Promoter hypermethylation patterns of p16, O6-methylguanine-DNAmethyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61: 939-942, 2001. (Pubitemid 32174408)
11. Jacinto FV, Ballestar E and Esteller M: Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques 44: 35-43, 2008. (Pubitemid 351251659)
12. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003. (Pubitemid 37448928)
13. Sardi I, Dal Canto M, Bartoletti R and Montali E: Abnormal c-myc oncogene DNA methylation in human bladder cancer: possible role in tumor progression. Eur Urol 31: 224-230, 1997. (Pubitemid 27101713)
14. Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC and Weghorst CM: Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 62: 5295-5300, 2002. (Pubitemid 35024605)
15. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG and Belinsky SA: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000.
16. Cheng YY, Jin H, Liu X, Siu JM, Wong YP, Ng EK, Yu J, Leung WK, Sung JJ and Chan FK: Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer 99: 2083-2087, 2008.
17. Pupa SM, Argraves WS, Forti S, Casalini P, Berno V, Agresti R, Aiello P, Invernizzi A, Baldassari P, Twal WO, Mortarini R, Anichini A and Menard S: Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene 23: 2153-2160, 2004. (Pubitemid 38482530)
18. Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, Muller M and Schulz WA: Downregulation of several fibulin genes in prostate cancer. Prostate 67: 1770-1780, 2007. (Pubitemid 350228729)
19. Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog 50: 571-579, 2011.
20. Twal WO, Czirok A, Hegedus B, Knaak C, Chintalapudi MR, Okagawa H, Sugi Y and Argraves WS: Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 114: 4587-4598, 2001. (Pubitemid 34082877)
21. Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R and Dahl E: The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene 27: 865-876, 2008. (Pubitemid 351186309)
22. Himmelfarb M, Klopocki E, Grube S, Staub E, Klaman I, Hinzmann B, Kristiansen G, Rosenthal A, Dürst M and Dahl E: ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer. Cancer Lett 204: 69-77, 2004. (Pubitemid 38117195)
23. Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T, Del Maestro R, Knuechel R and Dahl E: Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 8: 25, 2008.
24. Tsunematsu T, Kudo Y, Iizuka S, Ogawa I, Fujita T, Kurihara H, Abiko Y and Takata T: RUNX3 has an oncogenic role in head and neck cancer. PLoS One 4: e5892, 2009.
25. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002. (Pubitemid 34327521)
26. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG and Ito Y: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750, 2005. (Pubitemid 41297249)
27. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y and Bae SC: RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65: 9347-9354, 2002. (Pubitemid 41508002)
28. Chen W, Gao N, Shen Y and Cen JN: Hypermethylation down-regulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 25: 823-831, 2010.
29. Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T and Nakao A: Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int 5: 380-388, 2005.
30. Shiraha H, Nishina S and Yamamoto K: Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem 112: 745-749, 2011.
31. Nishina S, Shiraha H, Nakanishi Y, Tanaka S, Matsubara M, Takaoka N, Uemura M, Horiguchi S, Kataoka J, Iwamuro M, Yagi T and Yamamoto K: Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Oncol Rep 26: 523-531, 2011.
32. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23: 6736-6742, 2004. (Pubitemid 39280005)
33. Lee CW, Ito K and Ito Y: Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer. Cancer Res 70: 4243-4252, 2010.
34. Yanada M, Yaoi T, Shimada J, Sakakura C, Nishimura M, Ito K, Terauchi K, Nishiyama K, Itoh K and Fushiki S: Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 14: 817-822, 2005.
35. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL and Gaffney PM: Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64: 55-63, 2004. (Pubitemid 38114082)
36. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC, Tada K, Ong WY, Soong R, Voon DC and Ito Y: RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 25: 7646-7649, 2006. (Pubitemid 44924477)
37. Lee CW, Chuang LS, Kimura S, Lai SK, Ong CW, Yan B, Salto-Tellez M, Choolani M and Ito Y: RUNX3 functions as an oncogene in ovarian cancer. Gynecol Oncol 122: 410-417, 2011.
38. Kudo Y, Tsunematsu T and Takata T: Oncogenic role of RUNX3 in head and neck cancer. J Cell Biochem 112: 387-393, 2011.
39. Ito K: RUNX3 in oncogenic and anti-oncogenic signaling in gastrointestinal cancers. J Cell Biochem 112: 1243-1249, 2011.
40. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y and Sukumar S: RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520, 2006. (Pubitemid 44085605)
41. Guo B, Godzik A and Reed JC: Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem 276: 2780-2785, 2000.
42. Pickard MR, Edwards SE, Cooper CS and Williams GT: Apoptosis regulators Fau and Bcl-G are down-regulated in prostate cancer. Prostate 70: 1513-1523, 2010.
43. Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-Maarabouni M and Williams GT: Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res 11: R60, 2009.
44. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, Aozasa K and Morii E: Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 100: 429-433, 2009.
45. Perry SE, Robinson P, Melcher A, Quirke P, Bühring HJ, Cook GP and Blair GE: Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett 581: 1137-1142, 2007. (Pubitemid 46385936)
46. Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T and Aozasa K: Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 210: 75-84, 2006. (Pubitemid 44288183)
47. Seidel J, Kunc K, Possinger K, Jehn C and Lüftner D: Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration. Biochem Biophys Res Commun 414: 226-232, 2011.
48. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr and Yu Y: Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63: 4174-4180, 2003. (Pubitemid 36917943)
49. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB and Bast RC Jr: NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96: 214-219, 1999. (Pubitemid 29036079)
50. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y and Bast RC: ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22: 2897-2909, 2003. (Pubitemid 36648916)
51. Huang J, Lin Y, Li L, Qing D, Teng XM, Zhang YL, Hu X, Hu Y, Yang P and Han ZG: ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis. Mol Carcinog 48:130-140, 2009.